NASDAQ:ALVR AlloVir Q1 2024 Earnings Report $4.39 -0.05 (-1.13%) As of 09/18/2025 ProfileEarnings History AlloVir EPS ResultsActual EPS-$4.14Consensus EPS -$3.68Beat/MissMissed by -$0.46One Year Ago EPSN/AAlloVir Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlloVir Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time7:00AM ETUpcoming EarningsAlloVir's Q3 2025 earnings is scheduled for Monday, November 10, 2025, with a conference call scheduled on Tuesday, November 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AlloVir Earnings HeadlinesALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. ...August 6, 2025 | gurufocus.comALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 6, 2025 | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 19 at 2:00 AM | American Alternative (Ad)Kalaris Announces Closing of Merger with AlloVirMarch 18, 2025 | globenewswire.comAlloVir shareholders approve merger with Kalaris TherapeuticsMarch 14, 2025 | investing.comAlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of MergerMarch 13, 2025 | finanznachrichten.deSee More AlloVir Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email. Email Address About AlloVirAlloVir (NASDAQ:ALVR) is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses. AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings. ALVR105 is being evaluated for the treatment of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease, while ALVR106 and ALVR107 are targeted against BK virus and cytomegalovirus (CMV), respectively. A fourth candidate, ALVR108, is being developed as a multivirus therapy to target a combination of common viral pathogens. All programs are in various stages of clinical or preclinical development, reflecting the company’s commitment to advancing novel immunotherapies through regulatory milestones. Headquartered in Boston, Massachusetts, AlloVir serves a global market of transplant centers and healthcare institutions. The company’s leadership team brings together expertise in cell therapy, immunology and clinical development, supporting collaborations with academic centers and strategic partners to accelerate product development. AlloVir is publicly traded on the NASDAQ under the ticker symbol ALVR.View AlloVir ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
